drugset / Trial / NCT02799381
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
Timeline
- Start
- 2017-02-09
- Primary completion
- 2019-09-19
- Completion
- 2019-09-19
Publications
- Freire-Alvarez E, Vanni P, Kurca E, Lopez-Manzanares L, Kovacs N, Spanaki C, Gao T, Bergmann L, Sanchez-Solino O. Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study. Neurol Ther. 2024 Apr;13(2):437-447. doi: 10.1007/s40120-024-00583-z. Epub 2024 Feb 12.
- Freire-Alvarez E, Kurca E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sanchez-Solino O, Barbato LM. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial. Mov Disord. 2021 Nov;36(11):2615-2623. doi: 10.1002/mds.28703. Epub 2021 Jul 8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levodopa | Small molecule | — | Other |